Signadori Bio focuses on directly engineering monocytes in vivo to reprogram myeloid anti-tumour activity, aiming to overcome the immunosuppressive tumour microenvironment and unlock a new class of of...
Invivo Ventures AI will target early-stage companies applying AI to advance biotechnology and other science-driven domains. The fund is designed to capitalize on the surging momentum in AI, with deal ...
Innvierte SICC of CDTI Innovación invests in Integra Therapeutics, together with three co-investors, to develop a gene-editing platform for the treatment of oncological, autoimmune, and genetic disea...
The Series B extension financing was led by Bpifrance and joined by all existing shareholders, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...
Signadori Bio is a preclinical-stage biopharmaceutical company developing an innovative cell therapy platform to transform cancer treatment. The company’s proprietary platform originates from Gustav...
Neumirna was founded with the mission to revolutionize the treatment paradigms for challenging neurological conditions, and is at the forefront of RNA therapeutics, harnessing the power of microRNAs (...
Taking advantage of a long history of collaboration, the Catalan Institute of Finance (ICF) once again invests in Invivo Partners. On this occasion, the public promotion bank of the Generalitat invest...
Invivo Ventures III is strategically designed to propel the emergent field of synthetic biology, a domain where Invivo has already established a formidable presence through investments in pioneering c...
Invivo Ventures announces an investment of €2 million in EsoBiotec, a pioneering biotechnology company focused on developing in vivo engineered cell therapies for cancer treatment. This investment i...